Tyra Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TYRA research report →
About the company
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer.
- CEO
- Todd Harris
- IPO
- 2021
- Employees
- 60
- HQ
- Carlsbad, CA, US
Price Chart
- Market Cap
- $1.82B
- P/E
- -14.05
- P/S
- 0.00
- P/B
- 4.88
- EV/EBITDA
- -13.34
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -42.66%
- ROIC
- -36.34%
- Revenue
- $0 · 0.00%
- Net Income
- $-119,947,000 · -38.70%
- EPS
- $-2.01 · -33.11%
- Op Income
- $-132,762,000
- FCF YoY
- -35.27%
- 52W High
- $40.65
- 52W Low
- $9.47
- 50D MA
- $32.00
- 200D MA
- $27.01
- Beta
- 0.75
- Avg Volume
- 985.27K
Get TickerSpark's AI analysis on TYRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 13,160 |
| May 28, 26 | Verjee Rehan | other | 13,160 |
| May 28, 26 | Moran Susan | other | 13,160 |
| May 28, 26 | Simson Jake | other | 13,160 |
| May 28, 26 | Gulfo Adele M. | other | 13,160 |
| May 28, 26 | MORE ROBERT J | other | 13,160 |
| May 28, 26 | Rothenberg Stephen Michael | other | 13,160 |
| May 5, 26 | Warner Douglas J | other | 85,000 |
| May 5, 26 | Warner Douglas J | other | 25,000 |
| May 5, 26 | Fuhrman Alan | other | 67,000 |
Our TYRA coverage
Recent articles, reports, and earnings notes.
No research on TYRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TYRA report →Similar companies
Peers in the same neighborhood.